Minerva Neurosciences (NERV) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 05/06/24
Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business UpdatesGlobeNewsWire • 05/01/24
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business UpdatesGlobeNewsWire • 02/22/24
Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business UpdatesGlobeNewsWire • 11/07/23
Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business UpdatesGlobeNewsWire • 08/01/23
Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to MarketGlobeNewsWire • 06/28/23
Here's Why Minerva Neurosciences (NERV) Is a Great 'Buy the Bottom' Stock NowZacks Investment Research • 06/09/23
Minerva Neurosciences: Up About 250 Percent Since April With An FDA Catalyst AheadSeeking Alpha • 05/19/23
Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business UpdatesGlobeNewsWire • 05/15/23
Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in SchizophreniaGlobeNewsWire • 05/10/23
Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023GlobeNewsWire • 05/08/23
Minerva Neurosciences Reports Fiscal Year 2022 Fourth Quarter And Year End Financial Results And Business UpdatesGlobeNewsWire • 03/08/23
Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023GlobeNewsWire • 03/01/23
Minerva Neurosciences Reports Third Quarter 2022 Financial Results and Business UpdatesGlobeNewsWire • 11/09/22
Minerva Neurosciences to Report Third Quarter 2022 Financial Results and Business Updates on November 9, 2022GlobeNewsWire • 11/02/22